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Abstract Bacillus genus comprises an important
number of species which produce a wide range of
secondary metabolites displaying a broad spectrum of
activity and great structural diversity. The genome
sequences of an important number of species have
been published and a large number of orphan genes
reported. This review, covering all the literature in this
field up to end of 2011, summarizes and compares the
genetic potential of these organisms from the point of
view of bioactive nonribosomal peptide production
and their application as antibiotics, plant pathogen
biocontrol, promotion of plant growth, etc. The
biological and structural studies of the peptides
isolated from Bacillus species are revised and some
aspects of the biosynthesis of these metabolites and
related compounds are discussed.
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Introduction
Natural products continue to represent an excellent
source of lead structures for drug discovery. Tradi-
tional methods used to isolate microbial natural
products usually involve the collection and cultivation
of strains, extraction, bioassay-guided isolation and
structure elucidation. Unfortunately, this approach is
often frustrating because of a high rediscovery rate.
Thus, new concepts are required to increase the
probability of discovering new bioactive structures
(McAlpine et al. 2005).
However, an ever greater understanding of micro-
bial genomics has provided valuable insights into the
principles of natural product biosynthesis offering
promising alternatives for the discovery and engineer-
ing of new chemical entities. The post-genomic world
has shown that the traditional culture-based, bioassay-
guided strategies used to discover natural products
only provided access to a small fraction of the
biosynthetic capacity encoded in genomes. We now
know that most biosynthetic pathways are not
expressed at all, or just barely, under laboratory
conditions, or the products of these pathways have
simply been overlooked (Udwary et al. 2007).
Recent whole-genome sequencing programmes
have revealed that the biosynthetic potential of
microorganisms has been greatly underexplored,
relying as it does on traditional approaches. In fact,
the number of genes encoding biosynthetic enzymes in
various bacteria and fungi clearly outnumbers the
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known secondary metabolites of these organisms
(Challis 2008).
Bacillus represents just a small fraction of a larger
taxonomic consortium of endospore-producing bacte-
ria referred to as Bacillus sensu lato. The Bacillus
genus comprises a very large, diverse set of Gram-
positive bacteria that have one common yet distinct
feature: the ability to aerobically produce dormant
endospores when challenged by unfavorable growth
conditions. Thus, Bacilli are endospore-forming bac-
teria that are characterized by their rod-shaped cell
morphology, catalase production and their ubiquitous
distribution (Zeigler and Perkins 2009; Logan et al.
2007).
Members of the Bacillus genus are bacteria that
exploit a wide variety of organic and inorganic
substrates as nutrient sources. This ability to survive
and grow in such diverse ecosystems is based on the
production of robust endospores, their diverse phys-
iological properties, especially the production of
antibiotic molecules, and their growth requirements.
Bacilli are often thought of as microbial factories
given their production of a wide array of biologically
active molecules whose purpose it to suppress com-
petitive bacteria and fungi in plants (Stein 2005),
including peptide and lipopeptide antibiotics and
bacteriocins. Furthermore, a wide number of complete
and draft genome sequences are now available and
Bacillus may very well be one of the best chemically
characterised and most represented genera in the
genomic databases.
An overview of Bacillus sensu lato genus
and its genome sequences
The Bacillus sensu lato genus is both taxonomically
and metabolically diverse. Their production of anti-
microbial substances and sporulation capacity give
Bacillus strains a dual advantage in terms of their
survival in different habitats. They are phenotypically
and genotypically heterogenous (Slepecky and Hemp-
hill 2006), and consequently they exhibit quite diverse
physiological properties such as the ability to break
down many different substrates derived from plant and
animal sources, including cellulose, starch, proteins,
agar, hydrocarbons and even biofuels (Zeigler and
Perkins 2009). Bacilli isolated from a wide range of
environments, including plants and soil (Kunst et al.
1997; Priest 1993), hydrothermal vents (Takami et al.
2004), extreme environments (Rey et al. 2004; Takami
et al. 2000), sea water (Siefert et al. 2000), and a
shallow water column from an oligotrophic environ-
ment (Alcaraz et al. 2008) have been reported. The
presence of Bacillus in these different environments
brears witness to the broad metabolic capabilities of
this widely distributed genus.
Their primary habitat is the soil and associated
plants (B. amyloliquefaciens), rivers and estuarine
waters (B. coahuilensis), and they are well known for
their ability to control plant diseases through various
mechanisms, including the production of secondary
metabolites (Chen et al. 2009a). However, some
species are pathogenic to mammals (e.g. B. anthracis)
and insects (e.g. B. sphaericus, B. thuringiensis)
(Wipat and Harwood 1999).
As Bacillus spp. are characteristically omnipresent
in soils, exhibit high thermal tolerance and rapid
growth in liquid culture, readily produce resistant
spores and are considered to be a safe biological agent,
their potential as a biocontrol agent is considered to be
high (Shoda 2000). Additionally, their uses in insect
control, food industry, livestock and environmental
applications have been reported (Harwood and Cra-
nenburgh 2008).
The genomic sequences of several Bacillus species
have been made available over the last several years.
Recent research has identified biosynthetic genes that
code for a secondary metabolic pathway which are
clustered in microbial genomes. This observation has
facilitated their study and manipulation. Furthermore,
greater insight has been gained into their pathways
involving polyketide synthase (PKS) and nonriboso-
mal peptide synthetase (NRPS) assembly lines which
are responsible for the biosynthesis of these two large
classes of natural products (Marahiel 1992; Calderone
et al. 2006; Marahiel et al. 1993, 1997).
Recently, an interesting study, including a phylo-
genetic tree (Alcaraz et al. 2010), was carried out using
whole genome information to reconstruct their evolu-
tionary history taking advantage of the data set from
the complete and draft genomes of twenty Bacillus
isolated from a wide range of habitats, including a
newly sequenced Bacillus isolated from an aquatic
environment (Alcaraz et al. 2010).
An important number of projects are under way
which will contribute to a better understanding of their
ecological adaptations so as to be able to correlate
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particular sets of genes with their pathogenic potential
and the production of bioactive peptides and metab-
olites in general (Ravel and Fraser 2005).
Bacillus genus: comparative analysis of Bacillus
genome
The rate at which entire microbial genomes are being
sequenced has grown rapidly over the past years and is
revolutionising our understanding of microbial molec-
ular biology and genetics.
As already indicated, bacilli can be subgrouped
according to their ecophysiology (acidophily, alka-
liphily, halophily, psychrophily and thermophily) and
in terms of their metabolic diversity, into three major
classes: pathogenic, environmental uses and industrial
uses (Ravel and Fraser 2005). B. anthracis, B. cereus
and B. thuringiensis represent the pathogenic group,
while that the environmental bacilli are quite diverse
and include B. subtilis, B. amyloliquefaciens, B.
coahuilensis and B. halodurans. As for the class, the
most representative strains with industrial applications
are B. licheniformis and B. clausii. While this classi-
fication is useful in characterizing the metabolic
diversity of the genus, it provides no guidance for a
phylogenetic classification of the Bacillus for research
purposes (Alcaraz et al. 2010). Thus, four groups of
bacilli were defined following a classification system
based on orthologous relations among genes: (a) B.
anthracis–cereus–thuringiensis, (b) B. subtilis–li-
cheniformis–pumilus, (c) B. clausii–halodurans, and
(d) B. coahuilensis (Alcaraz et al. 2010).
Comparative analysis of the genome sequence of
the related environmental isolates clearly shows that
B. amyloliquefaciens, B. subtilis and B. licheniformis
are closely related and quite distinct from the B. cereus
group of organisms (B. anthracis, B. cereus and B.
thuringiensis). Despite a high degree of chromosomal
similarity among these genomes, significant differ-
ences in cell wall and spore coat proteins that
contribute to the survival and adaptation in specific
hosts were identified (Anderson et al. 2005).
Bacillus clausii–halodurans form the group of
alkalophiles and halotolerant strains. Interestingly, this
group has a fewer than average number of genes
involved in the cell wall/membrane/envelope category.
Additionally, there are several known differences in
the cell wall composition of B. clausii–halodurans
compared to B. subtilis, such as the presence of the major
cell wall component teichurono-peptide (Takami et al.
2000).
Pathogenic Bacilli group
Bacillus anthracis, B. cereus, and B. thuringiensis are
genetically very closely related, a fact which has led to
a proposal for their consideration as a single species
(Radnedge et al. 2003) but no consensus has been
reached in this regard. This ambiguous taxonomic
state of the B. cereus group illustrates the difficulties
encountered in species definition within bacterial
systematics, especially in the genomic era.
Several interesting reviews and papers have
recently been reported on comparative genome anal-
ysis of the B. cereus group (Rasko et al. 2005; Read
et al. 2002, 2003; Ivanova et al. 2003). The analysis of
representative members of Bacillus genomes has led
to the discovery of the shared and singular metabolic
and virulence capability of each species. The presence
of specific genes with functions related to spore coat,
exopolysaccharide biosynthesis and membrane trans-
port has revealed significant differences despite the
high level of chromosomal similarity among B. cereus
group bacteria. In this regard, recent studies have
demonstrated differences in gene order, chromosomal
rearrangements, nucleotide variations and remnant
phages, suggesting that B. anthracis diverges from B.
cereus and B. thuringiensis and represents a distinct
genetic lineage(Read et al. 2002).
B. cereus
Discussion of the classification of B. cereus group
strains is not only of academic and taxonomic interest,
but is also important from a public health perspective
because genes encoding the cytotoxins associated with
diarrhoeal disease and other opportunistic B. cereus
infections are generally chromosomally encoded and
are present in all species of the B. cereus group,
although they are silent in B. anthracis (Arnesen et al.
2008). B. cereus is frequently isolated as a contam-
inant of a number of foods and can occasionally be an
opportunistic human pathogen (Helgason et al. 2000;
Drobniewsk 1993). Thus, B. cereus isolates harbour-
ing B. anthracis virulence factors have been detected
in cases of severe anthrax-like illnesses (Hoffmaster
et al. 2004).
Phytochem Rev (2013) 12:685–716 687
123
B. anthracis
Bacillus anthracis is a potent mammalian pathogen
and potential bioterrorist agent which shares so much
genetic material with B. cereus and B. thuringiensis
that it is difficult to distinguish it from the other
species. All three Bacillus species are prevalent in
many environments and considerable efforts have
been made to define the genetic differences specific to
B. anthracis in order to design specific DNA-based
identification protocols. Thus, a great many compar-
ative analyses of B. anthracis to closely related
bacteria genome sequences and comparative genome
studies of B. cereus with B. subtilis and B. anthracis
genomes have been performed by many scientists
(Read et al. 2002, 2003; Ivanova et al. 2003; Keim
et al. 2009).
A detailed comparative analysis of the genomes of
B. cereus and B. anthracis revealed a small subset of
genes unique to either species (Rasko et al. 2005). The
majority of these genes are located at the terminus of
replication, indicating that genome plasticity mostly
occurs in that region. These data suggest a history of
insertion and/or deletion in the evolution of the B.
cereus group. It was observed that, in many cases,
genes found at a specific position in one genome were
replaced with others at the corresponding loci in
another (Rasko et al. 2005).
B. thuringiensis
Bacillus thuringiensis is the most well-known and
thoroughly studied example of an entomopathogenic
bacterium which produces parasporal protein crystals
in association with spore formation (Bode 2009).
These protein toxins lyse the insect after ingestion
(Zhou et al. 2008). Therefore natural and genetically
engineered strains of B. thuringiensis have been used
commercially to control pests of many representatives
of the Lepidoptera, Diptera, and Coleoptera orders.
Thus, B. thuringiensis has been widely exploited in
agriculture as an insecticide, thanks to the presence of
plasmid-borne crystal toxin genes (Schnepf et al.
1998).
Virulence against insects is believed to be conferred
by multiple factors and the genomic sequence has
identified numerous secondary metabolite gene clus-
ters that could also contribute to the insecticidal
activity of B. thuringiensis (Rasko et al. 2005).
Additionally, the genes encoding the Bt-toxins have
been successfully transferred into cotton, corn, soy-
bean, and rice conferring resistance to insect pests thus
leading to a significant economic benefit (Zhou et al.
2008). Besides protein toxins, B. thuringiensis is also a
producer of an acyl homoserine lactone lactonase
which can eliminate the pathogenicity of plant path-
ogenic bacteria, and zwittermicin, a potent antibiotic
and antifungal compound (Kevany et al. 2009).
Furthermore, the complete genome sequence of
several strains of B. thuringiensis, such as B. thurin-
giensis Al Hakam (Challacombe et al. 2007) and B.
thuringiensis BMB171 (He et al. 2010), has been
reported. A comparative analysis of the genomes of
both strains of B. thuringiensis has been described (see
Table 1).
Environmental Bacilli group
The bacterium B. subtilis was first described in 1872
by Ferdinand Cohn and is a species that is second only
to Escherichia coli in terms of the level of detail at
which it has been studied (Ravel and Fraser 2005).
The B. subtilis group includes the most intensively
studied of the bacilli, including species such as B.
subtilis itself, B. amyloliquefaciens and B. lichenifor-
mis which are of industrial importance (Harwood
1992), and B. coahuilensis, one of the most recent
Bacillus species reported from a marine environment
(Cerritos et al. 2008).
B. subtilis
Bacillus subtilis has been a paradigm for the genetics
of Gram-positive bacteria for more than 30 years. It
Table 1 Genomic properties of B. thuringiensis
Species Strain Genome size (Mb) % GC No. of protein-coding genes No. of tRNAs No. of rRNA operons
B. thuringiensis Al Hakam 5.31 35 4,969 105 13
BMB171 5.64 35.3 5,088 plus 276 on plasmids 104 14
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has a particularly well-developed natural transforma-
tion system that proved invaluable for genetic manip-
ulation and analysis in the pre-recombinant DNA
technology era.
The B. subtilis genome sequence is the first
complete genome of a free-living soil and rhizosphere
bacterium which was accomplished by an interna-
tional consortium of 46 laboratories worldwide (Kunst
et al. 1997; Stewart et al. 2009). Its genome, composed
of 4,214,810 base pairs comprises 4,100 protein-
coding genes. Of these protein-coding genes, 53 % are
represented once while a quarter of the genome
corresponds to several gene families that have been
greatly expanded by gene duplication. The identifica-
tion of five signal peptidase genes, along with several
genes for components of the secretion apparatus
(Tjalsma et al. 1997) is important given the capacity
of Bacillus strains to secrete large amounts of indus-
trially important enzymes. Many of the genes are
involved in the synthesis of secondary metabolites,
including antibiotics. The genome contains at least ten
prophages or remnants of prophages, indicating that
bacteriophage infection has played an important
evolutionary role in horizontal gene transfer, in
particular in the propagation of bacterial pathogenesis
(Kunst et al. 1997).
Data derived from the genome sequence (Moszer
1998) and the systematic functional analysis pro-
gramme (Hunt et al. 2006), together with the wealth of
knowledge already available for this organism, has
opened the door to new opportunities in studying the
behaviour and ecology of this soil and plant growth-
promoting rhizobacterium at the molecular level.
B. amyloliquefaciens
Bacteria that are associated with plant roots and exert
beneficial effects on plant development are referred to
as plant growth-promoting rhizobacteria (Kloepper
et al. 1980). They competitively colonize plant roots
and can simultaneously act as biofertilizers and as
antagonists (biopesticides) of recognized root patho-
gens including bacteria, fungi and nematodes. There is
a large body of literature reporting the potential use of
rhizosphere-associated bacteria in stimulating plant
growth and biocontrol agents (Argüelles-Arias et al.
2009; Somers et al. 2004; Lugtenberg and Kamilova
2009). Among these, several strains belonging to the
Bacillus genus, particularly to the B. subtilis and B.
amyloliquefaciens species, were reported as being
effective in the biocontrol of multiple plant diseases
caused by soilborne (Leclere et al. 2005; Chen et al.
2009b) or post-harvest pathogens (Senghor et al. 2007;
Yang et al. 2008; Kotan et al. 2009). Members of the
Bacillus genus are thus among the beneficial bacteria
mostly exploited as microbial biopesticides. Bacillus-
based products account for approximately half of the
commercially available bacterial biocontrol agents
(Fravel 2005).
The plant root-colonizing B. amyloliquefaciens
strain FZB42 is an environmental strain which is
distinguished from the domesticated model organism
B. subtilis 168 by its ability to stimulate plant growth
and to suppress plant pathogenic organisms (Idriss
et al. 2002).
Bacillus amyloliquefaciens FZB42 genome analy-
sis revealed the presence of numerous gene clusters
involved in synthesis of nonribosomally synthesized
cyclic lipopeptides (Chen et al. 2009c) and polyketides
(Chen et al. 2007; Koumoutsi et al. 2004) with proven
antimicrobial action (Koumoutsi et al. 2007).
B. coahuilensis
Bacillus coahuilensis is a sporulating bacterium
isolated from the water column of a desiccation
lagoon in the Cuatro Ciénegas Basin (CCB) in the
central part of the Chihuahan desert (Coahuila,
Mexico). A major question yet to be answered is
whether bacteria from CCB are ancient marine
bacteria that adapted to an oligotrophic system poor
in NaCl, rich in sulfates and with extremely low
phosphorus levels. The B. coahuilensis genome is the
smallest genome of a Bacillus species (3.35 Megaba-
ses) sequenced to date and provides insights into the
origin, evolution, and adaptation of B. coahuilensis to
the CCB environment. The size and complexity of the
B. coahuilensis genome reflects the adaptation of an
ancient marine bacterium to a novel environment,
providing support for a ‘‘marine isolation origin
hypothesis’’ that is consistent with the geology of
CCB. This genomic adaptation includes the acquisi-
tion, through horizontal gene transfer, of genes
involved in phosphorous utilization efficiency and
adaptation to particularly luminous environments
(Alcaraz et al. 2008).
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Industrial uses Bacilli group
B. licheniformis
Bacillus licheniformis is a Gram-positive, spore-
forming bacterium widely distributed in the environ-
ment as a saprophytic organism. There are numerous
commercial and agricultural uses for B. licheniformis
and its extracellular products (Erickson 1976).
Bacillus subtilis and B. licheniformis are closely
related species that feature similar saprophytic life-
styles in soils. Both species are known for their ability
to secrete numerous proteins into the surrounding
medium, some in quite high amounts (Voigt et al.
2006). This enables them to break down a variety of
high molecular weight substances found in soils and
use the resulting products as nutrients to sustain
growth or to ensure their survival under scarce nutrient
conditions. In addition, the ability to secrete large
amounts of proteins has been exploited by the
fermentation industry for some time now, especially
for the production of industrial enzymes including
several proteases, a-amylase, penicillinase, pentosan-
ase, cycloglucosyltransferase, b-mannanase and sev-
eral pectinolytic enzymes (Erickson 1976).
A comparative study of the genome sequence of B.
licheniformis with related environmental isolates
clearly shows that B. licheniformis is closely related
to those of the B. subtilis group and is quite distinct
from B. cereus group organisms (Rey et al. 2004).
Two similar strains of B. licheniformis (ATCC
14580 and DSM13) (Rey et al. 2004; Veith et al. 2004)
were sequenced by two different groups and published
one shortly after the other.
Bacillus subtilis and B. licheniformis share approx-
imately 80 % of their proteome. However, there are
notable differences in the numbers and locations of
prophages, transposable elements and a number of
extracellular enzymes and secondary metabolic path-
way operons that distinguish these species.
Bacillus licheniformis uses cellulose as it sole
source of carbon and energy. Additionally, B. lichen-
iformis codes for activities that enable growth on a
broad range of polysaccharides, particularly advanta-
geous in the competitive soil environment and also of
interest for biotechnological applications. Many new
genes of potential interest for biotechnological appli-
cations were found in B. licheniformis; candidates
include proteases, pectate lyases, lipases and various
polysaccharide-degrading enzymes (Ravel and Fraser
2005).
B. halodurans
Generally, alkaliphilic Bacillus strains cannot grow or
grow poorly under neutral pH conditions, but grow
well at pH [9.5. The complete genomic sequence of
the alkaliphilic bacterium, strain B. halodurans C-125,
has been determined (Takami et al. 2000) and its
genome compared with that of B. subtilis.
Alkaliphilic bacteria studies are focused on the
enzymology, physiology and molecular genetics of
these microorganisms to elucidate their mechanisms
of adaptation to alkaline environments. Industrial
applications of these microbes have been investigated
and some enzymes, such as proteases, amylases,
cellulases, and xylanases, have been commercialized
(Takami et al. 2000).
B. clausii
Bacillus clausii is a facultative alkalophilic bacillus
which is commercially used in the production of
alkaline proteases for detergents (Saeki et al. 2007),
and as a probiotic (Bozdogan et al. 2003) administered
to humans to prevent the gastrointestinal side-effects
caused by oral antibiotic therapy. Ingestion of high
quantities of spores is thought to restore an intestinal
flora following the destruction of normal flora by
antibiotics.
Over the last years an important number of papers
and reviews on the proteomics of the Bacillus genus
have appeared providing insights into how proteomics
can be used to bring the virtual life of genes to the real
life of proteins (Hecker and Voelker 2004).
Peptide metabolites from Bacillus spp.
Bacillus species produce a wide array of biologically
active molecules including polyketides, lipopeptides,
siderophores and peptides. Polyketides (Hamdache
et al. 2011) are beyond the scope of this review, which
focuses more specifically on nonribosomal bioactive
peptides.
Nutritional stress conditions lead to the activation
of a number of processes affecting survival rate.
Activities induced include the development of genetic
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competence, sporulation, and synthesis of degradative
enzymes, motility, and antibiotic production. The
genes that function in these processes are activated
during the transition from exponential to stationary
phase and are controlled by mechanisms that operate
primarily at the level of transcription initiation
(Jedrzejas and Huang 2003).
From the point of view of biosynthesis, Bacillus
genus species produce two different classes of pep-
tides: ribosomal and nonribosomal peptides, which are
biosynthesized by two different biosynthetic pathways
allowing the incorporation of such unusual (non-
proteinaceous) constituents: (a) the nonribosomal
synthesis of peptides by large megaenzymes, nonrib-
osomal peptide synthetases (NRPSs) and (b) the
ribosomal synthesis of linear precursor peptides that
are subjected to post-translational modification and
proteolytic processing.
Ribosomal bioactive peptides
Bacterial antimicrobial peptides produced by ribo-
somal synthesis are commonly referred to as bacteri-
ocins. This is a heterologous group of proteinaceous
antimicrobial substances produced by bacteria from
every major lineage. They display a high degree of
target specificity against related bacteria although
many have a wider spectrum of activity (Abriouel
et al. 2011).
Unlike nonribosomal peptides (NRPs), ribosomal
peptide (RP) natural products are unable (as far as is
known) to explore amino acids beyond the canonical 20
proteinogenic amino acids, limiting their structural
diversity to some degree. However, they can be
extensively post-translationally modified and such
modifications give rise to products with many features
resembling those of NRPs. In fact, many of the
modifications commonly thought of as ‘‘nonribosomal’’
are also found in ribosomally synthesized peptides.
Other RPs has unique modifications that allow them to
explore greatly expanded chemical spaces in a manner
similar to the NRPs (McIntosh et al. 2009).
A great advantage of the RPs is that their sequences
may be modified by simple manipulation of a few
codons in contrast to NRPs which require extensive
genetic engineering to incorporate changes. Thus,
ribosomal natural products have many -but not all- of
the structural advantages of the NRPs, and in addition
they are easier to modify to produce novel bioactive
compounds. Many excellent reviews of individual RP
classes have recently come out such as lantibiotics,
microcins and others. Especially relevant is the one
concerning bacteriocines recently published by A.
Gálvez et al. (Abriouel et al. 2011).
Furthermore, the number of known peptide natural
products that are synthesized via the ribosomal
pathway has grown rapidly and their remarkable
structural and functional diversity may lead to novel
pharmaceutical applications. The strategies used for
the identification of these ribosomally synthesized and
posttranslationally modified peptides (RiPPs) and the
structures of newly identified compounds have
recently been reviewed (Velasquez and van der Donk
2011). The reader is referred to these reviews for a
more in-depth look at individual RP classes.
The number of RP families has increased consid-
erably in recent years with the discovery of the
biosynthetic origin of cyanobactins, thiopeptides,
microviridins and amatoxins. These findings have
shown that the ribosomal world is much more diverse
than originally thought, and have revealed an enor-
mous structural diversity that is just beginning to be
appreciated (McIntosh et al. 2009; Oman and van der
Donk 2010).
Nonribosomal bioactive peptides
Nonribosomal peptides are a structurally diverse class of
peptides with various functions, such as cytostatic,
immunosuppressive, antibacterial, or antitumor proper-
ties. These secondary metabolites differ from peptides
of ribosomal origin in several ways. Their length is
limited to a mere 20 building blocks, roughly, and
mostly a circular or branched cyclic connectivity is
found. Furthermore, aside from the proteinogenic amino
acids, a larger variety of chemical groups is found in
these bioactive compounds: D-configurated amino
acids, fatty acids, methylated, oxidized, halogenated,
and glycosylated building blocks. These functional and
structural features are known to be important for
bioactivity, and often natural defense mechanisms are
thus evaded (Schoenafinger and Marahiel 2009).
The genes encoding the multifunctional enzymes
that catalyse nonribosomal synthesis of the peptide
antibiotics are organized in operons that are transcrip-
tionally induced in response to nutritional stress. The
regulation of antibiotic biosynthesis operons is accom-
plished through the interaction of diverse factors
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which also function in controlling other stationary-
phase-induced processes in Bacillus. Peptide antibi-
otic biosynthesis genes are regulated by factors as
diverse as the early sporulation gene product SpoOA,
the transition-state regulator AbrB, and gene products
(ComA, ComP, and ComQ) required for the initiation
of the competence developmental pathway (Marahiel
et al. 1993).
In spite of their structural heterogeneity, the nonrib-
osomal peptide antibiotics are biosynthesized by the
iterative coupling of amino acids and share a common
mode of synthesis, the multicarrier thiotemplate mech-
anism which is carried out by the large multidomain
enzymatic machineries, the so-called nonribosomal
peptide synthetases (NRPSs). NRPS are megaenzymes
organized in iterative functional units called modules
that catalyze the different reactions leading to polyke-
tide or peptide transformation. The first crystal structure
of an entire module of domains from an NRPS system
has recently been reported (Weissman and Mueller
2008). These megasynthetases build the growing chains
as a series of elongating acyl-S-proteins, covalently tied
to the terminal thiol of phosphopantetheinyl arms, with
themselves hitched to side chains of serine residues of
carrier protein domains in the assembly line (Fischbach
and Walsh 2006; Walsh 2008).
Each module is subdivided into several catalytic
domains responsible for each biochemical reaction. A
typical NRPS module usually comprises 1,000 amino
acid residues approximately and is responsible for one
reaction cycle. Each elongation cycle in nonribosomal
peptide biosynthesis needs the cooperation of three
basic domains:
(a) adenylation domain, which generates an enzy-
matically stabilized aminoacyl adenylation.
(b) peptidyl carrier domain, which transfer and
bound the adenylated amino acid substrate by a
thioester bond.
(c) condensation domain catalyzes formation of a
new peptide bond. The linear organization of
such core units (a–c) ensures the coordinated
elongation of the peptide product. The basic set
of domains within a module can be extended by
substrate modifying domains, including domains
for substrate epimerization, hydroxylation, meth-
ylation and heterocyclic ring formation, which
act as independent catalytic units (Finking and
Marahiel 2004).
Three major chemical routes for disconnection of
the covalent thioester linkages of NRPS acyl chains
when they reach the most downstream carrier protein
domains on assembly lines have been observed. A
thioesterase domain, which in some cases is respon-
sible for the cyclization of the peptide, is usually
present in the last module to ensure the cleavage of the
thioester bond between the emerging peptide and the
last PCP domain (Walsh 2008).
The logic of NRPS assembly lines is modular
(Marahiel et al. 1997), and the encoding genes in
microbial genomes are almost always clustered. The
molecular organization of these peptides synthetases
and the regulation of the corresponding biosynthesis
genes have been analyzed and reported (Marahiel et al.
1993). This basic mechanism can result in great
chemical variety of peptide products containing
hydroxy-, L-, D-, or unusual amino acids, which can
be further modified by N methylation, acylation,
glycosylation or heterocyclic ring formation. More
than 300 different residues are known to be incorpo-
rated into these peptide secondary structures (Hancock
and Chapple 1999).
The therapeutic potential of peptides of nonribos-
omal origin is well recognized. In addition, recent
years have seen the discovery of a growing number
and wide diversity of peptides that are biosynthesized
by a nonribosomal pathway (Frueh et al. 2008).
However, in spite of the high number, wide
structural diversity and growing number of nonribos-
omal peptides, to our knowledge no classification
scheme has been devised for this class of Bacillus
peptides. This is probably a result of the confusing
information about structures of some reported pep-
tides, lack of information on many of these peptides
amino acid sequences or the vast diversity of nonrib-
osomal peptides produced by bacilli. This review has
been organized on the base of the peptides/amino acid
sequences molecular structure point of view. Two
major groups can be differenced, cyclic and linear
peptides, and both groups have been arranged on the
base of the structure-peptides number.
Cyclic peptides
Tridecapeptides
The antifungal peptide antibiotic, mycobacillin (1)
(Fig. 1), was isolated from the B3 strain of B. subtilis.
The study of the physicochemical properties of
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mycobacillin (1) shows that it is a polypeptide
consisting of five aspartic acid residues, two glutamic
acid and two tyrosine residues and one residue each of
serine, alanine, leucine and proline (Majumdar and
Bose 1960).
The biosynthesis of the cyclic mycobacillin (1) is
an alternative to the thiotemplate mechanism of
peptide antibiotic biosynthesis. Instead of two-step
activation of amino acids, a single-step mechanism
with formation of aminoacylphosphate was proposed.
The enzyme complex that catalyzes the synthesis of
mycobacillin (1) is separated into three fractions:
(A) which operates during synthesis of the first
pentapeptide; (B) which catalyzes the synthesis of
the nonapeptide; and (C) which catalyzes synthesis of
the final product (Mannanov and Sattarova 2001).
Dodecapeptides
Cereulide (2) (Fig. 1), is a cyclic dodecadepsipeptide
produced by B. cereus which acts as a potassium
ionophore. Cereulide (2), an emetic toxin, is heat, acid
and alkaline stable as well as resistant to proteolysis by
trypsin and pepsin, making it of particular concern to
the food industry, as existing emetic toxin is not
inactivated by processing methods (Ehling-Schulz
et al. 2004). The emetic syndrome is usually charac-
terized by nausea and vomiting, however, more severe
cases have also been reported, leading for instance to
acute liver failure (Posfay-Barbe et al. 2008).
In light of the increasing number of serious food
borne outbreaks caused by emetic B. cereus, tran-
scriptional kinetic analyses of cereulide synthetase
genes with respect to growth, sporulation and emetic
toxin production have been reported (Dommel et al.
2011).
Cereulide (2) is closely related to the antibiotic
valinomycin (Agata et al. 1994). Both compounds are
known as K?-ionselective ionophores and cause a
potassium-dependent drop in the transmembrane
potential of mitochondria arising from the uptake of
a K?-ioncharged ionophore complex (Makarasen et al.
2009). The cereulide peptide synthetase of the emetic
B. cereus reference strain F4810/72 was found to be
located on a pXO1-like plasmid, designated pBCE,
and was identified as a 24 kb ces gene cluster
comprising seven codingDNA sequences(Ehling-
Schulz et al. 2006).
Homocereulide, isolated from the marine bacte-
rium B. cereus SCRC, is very similar to cereulide (2).
It differs only in the presence of a methyl group. Thus,
the stereochemistry of homocereulide was deduced to
be cyclo[-(D-Hic-D-Ala-L-Hiv-L-Val-)2-D-Hic-D-Ala-
L-allo-Hmv-D-Val-]. Both homocereulide and cereu-
lide (2), exhibited extremely potent cytotoxicity and
activity against the murine leukemia cell line P388 and
the colon 26 tumor cell line (Sheng et al. 1995).
Undecapeptides
In 1976, Shoji et al. (1976a) reported the isolation of an
amphoteric acylpeptide antibiotic named brevistin (3)
(Fig. 1) from the culture broth of B. brevis 342-14
which is active against Gram-positive bacteria in vitro
and in vivo. Brevistin (3) is thought to be a complex of
undecapeptides, consisting of a major peptide (80 %)
Fig. 1 Trideca-, dodeca-
and undecapeptides reported
from Bacilli
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containing isoleucine and a minor (20 %) containing
valine: isoleucine or valine is present in the same
position of the sequence. The constituent fatty acid was
elucidated to be anteisononanoic acid by gas chroma-
tography-mass spectrometry (Shoji and Kato 1976a).
Esein and bresein are two cyclopeptides produced
by B. brevis (Zharikova et al. 1975). Esein is
amphoteric and has one free NH2 group and 11 amino
acids (Radzhapov et al. 1968). Bresein is basic and it
has two NH2 groups. The biosynthesis of these




Fengycin and related compounds
Bacillus strains produce a broad spectrum of bioactive
nonribosomal lipopeptides with great potential for
biotechnological and biocontrol applications and
include lipopeptides of the iturin, surfactin and
fengycin families. All these lipopeptides feature a
lipophilic fatty acid chain and a hydrophilic peptide
ring and exhibit powerful biocontrol activities (Touré
et al. 2004). They are amphiphilic cyclic peptides
composed of 7 a-amino acids (surfactins and iturins)
or 10 a-amino acids (fengycins) linked to one unique
b-amino fatty acid (iturins) or b-hydroxy fatty acid
(surfactins and fengycins). The length of the fatty acid
chain varies from C13 to C16 for surfactins and from
C14 to C17 for iturins. Lipopeptides have low toxicity,
high biodegradability and are environmentally
friendly compared with chemical pesticides. Further-
more, some lipopeptides show great promise as
antitumour, antiviral and antimycoplasma agents
(Yang et al. 2006).
Fengycin (4) and the closely related plipastatin
(Fig. 2) are cyclic lipodecapeptides containing a
b-hydroxy fatty acid with a side chain length of
16–19 carbon atoms. Four D-amino acids and ornithine
(a non-proteinogenic residue) have been identified in
the peptide portion of fengycin (4). It is specifically
active against filamentous fungi and inhibits phos-
pholipase A2 (Nishikiori et al. 1986a).
Fengycin (4) is a lipopeptide biosurfactant (Vater
et al. 2002) produced by several Bacillus species. This
Fig. 2 Decapeptides
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lipopeptide can function as a biocontrol agent, and
exhibits fungicidal, bactericidal, and insecticidal
activity (Vanittanakom et al. 1986). It is known to
develop antifungal activity against phytopathogen
fungi and to exhibit hemolytic activity. Like most of
the natural antimicrobial peptides, fengycin (4) likely
acts by increasing the permeability of the target cell’s
plasma membrane (Deleu et al. 2008). The inhibition
is antagonized by sterols, phospholipids and oleic
acid, whereas two other unsaturated fatty acids
increase the antifungal effect (Vater et al. 2002).
The plipastatins, isolated from B. subtilis (Tsuge et al.
1996, 1999) and B. cereus (Umezawa et al. 1986), are
very similar to fengycins. They differ only in the
stereochemistry of the Tyr residues (L to D diastereoiso-
mers) (Volpon et al. 2000). The antimicrobial spectrum
of plipastatins is still mostly unknown but was shown to
inhibit the phospholipase A2 (Umezawa et al. 1986), an
enzyme involved in a number of physiologically
important cellular processes such as inflammation,
acute hypersensitivity and blood platelet aggregation
(Hirata and Axelrod 1980). As for the other lipopeptides
produced by B. subtilis, plipastatins are biosynthesised
as a mixture of isoforms characterised by variations in
both the nature of the hydrophobic tail and the amino
acid composition (Nishikiori et al. 1986b). The hydro-
phobic tail is a 3(R)-hydroxy hexadecanoic acid
(plipastatins A1 and B1) or a 14(S)-methyl-3(R)-
hydroxy hexadecanoic acid (plipastatins A2 and B2)
while the amino acid sequence differ in position 6 with a
D-Ala (plipastatin A1 and A2) substituted by a D-Val
(plipastatin B1 and B2) (Volpon et al. 2000).
Maltacines comprise a family of peptide lactone
antibiotics related to fengycin (4), produced by a strain
of B. subtilis, of which 13 of the molecules have been
studied, B1a, B1b, B2a, B2b (Hagelin 2005a,
527–538), C1a, C1b, C2a, C2b (Hagelin 2005b,
1276–1286), D1a, D1b, D1c (Hagelin 2005c,
1287–1299), E1a and E1b (Hagelin 2005d). These
are suggested to be cyclo-4,12 peptide lactones whose
members have major parts of their primary sequences
in common. Position 4 in all members was thought to
be occupied by a hydroxyamino-acid that is part of the
lactone ring (Hagelin et al. 2007). Maltacines present
activity against Gram-positive bacteria such as Staph-
ylococcus aureus, some Gram-negative bacteria and
the opportunistic fungi Candida albicans, Tricophyton
mentagrophytes and Aspergillus fumigatus (Hagelin,
2005d).
Polymyxin family and related compounds
Antimicrobial polycationic peptides have been iso-
lated from a wide variety of species and include the
microbial polymyxins (Vogler and Studer 1966).
Polymyxins, including polymyxins A (Wilkinson
and Lowe 1966), B (5), C (Charbonneau et al. 1998),
D (Brownlee et al. 1949), E, F, M, T1, S1 and P, are a
wide family of closely related peptide antibiotics
containing a cycloheptapeptide ring with a C-8 or C-9
fatty acid attached through an amide bond (Fig. 2)
(Storm et al. 1977). These antibiotics are active against
many Gram-negative and a few Gram-positive micro-
organisms (Newton 1956), but their mode of action is
still not precisely known.
The cationic surfactant polymyxin B (5) (a mixture
of polymyxins B1 and B2) is an a,c-diaminobutyric
acid (DAB)-rich decapeptide from Paenibacillus
polymyxa exhibiting antimicrobial and lipopolysac-
charide (LPS)-antagonistic activities. It is effective
against Gram-negative bacteria (Rosenberg and Ron
1999). Polymyxin B nonapeptide is a derivative of
polymyxin B (5) (Bhattacharjya et al. 1997).
Polymyxin E, a mixture of polymyxins E1 and E2
isolated from P. polymyxa, designates a multicompo-
nent branch of the polymyxin family that is commonly
known as colistin. Polymyxin E1, the major constit-
uent, is considered to be the active pharmaceutical
ingredient for therapeutic indications. It contains one
D-leucine, one L-leucine, six L-a,c-diaminobutyric
acid, and two L-threonine residues. The cyclic struc-
tures of the polymyxins E1 and theirs analogs were
selective for Gram-negative bacteria and showed
potent inhibitory activity against E. coli and against
Pseudomonas aeruginosa. In contrast, the acyclic
analogs of these peptides showed no antimicrobial
activity (Kline et al. 2001).
Polymyxin F is an antibiotic produced by B.
circulans ATCC No 31228, which is comprised of
2,4-diaminobutyric acid (DAB), Thr, Ser, Ile and Leu
at a ratio of 5:1:1:1:2. The hydrolysate also contains
three extractable fatty acids identified as 6-methyloc-
tanoic acid, isooctanoic acid and octanoic acid, with
relative abundances of 78:19:3, respectively. Poly-
myxin F possesses a pattern of antimicrobial activity
that is similar to that of polymyxin B (5) (Parker et al.
1977).
Mattacin (polymyxin M) possesses an amide link-
age between the C-terminal threonine and the side
chain amino group of the diaminobutyric acid residue
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at position 4. It contains an (S)-6-methyloctanoic acid
moiety attached as an amide at the N-terminal amino
group, one D-leucine, six L-a,c-diaminobutyric acid
and three L-threonine residues. Mattacin was capable
of inhibiting the growth of a wide variety of Gram-
positive and Gram-negative bacteria, including sev-
eral human and plant pathogens with activity compa-
rable with purified polymyxin B (5), a commercial
antibiotic (Martin et al. 2003).
Two members of the polymyxin group of antibiot-
ics, named polymyxins S1 and T1, have been isolated
from B. polymyxa Rs-6 and B. polymyxa E-12,
respectively. These antibiotics are strong basic sub-
stances soluble in water, and are primarily active
against Gram-negative bacteria in vitro and in vivo,
though polymyxin T1 exhibits somewhat higher
activities against Gram-positive bacteria than other
polymyxin group antibiotics do (Shoji et al. 1977a). In
both polymyxins, S1 (Shoji et al. 1977b) and T1, the
constituent fatty acid proved to be anteisononanoic
acid. Another antibiotic complex, polymyxin P, was
also isolated from B. polymyxa T-39 (Kimura et al.
1969).
Circulins are a group of basic polypeptides related
to polymyxins which are produced by B. circulans
ATCC 14040 (Fig. 2) (Fujikawa et al. 1965). The
isooctanoyl group is the terminal group of the side-
chain. Circulin A (6) (Vaara and Vaara 2009) and
circulin B are similar to polymyxin insofar as their
ability to inhibit the growth of Gram-negative more
strongly than Gram-positive bacteria, but have a
somewhat different bacterial spectrum. They are
inactivated by crude trypsin while polymyxin is not
and are more toxic than polymyxin (Murray et al.
1949).
A strain of B. polymyxa (BP1), isolated from
cauliflower seeds, inhibited the growth of microbial
phytopathogens. Two antibacterial substances were
isolated and purified from culture broth. The first
compound was named gavaserin because it contained
glutamic acid, alanine, valine, serine and 2,4-diamin-
obutyric acid, and octanoic acid. No fatty acid was
detected in the second compound, which was named
saltavalin because it contained serine, alanine,
leucine, threonine, valine, and 2,4-diaminobutyric
acid (Pichard et al. 1995).
Bacitracin family
Bacitracins are synthesized by certain strains of B.
licheniformis or B. subtilis (Pfaender et al. 1973; Ming
and Epperson 2002). Although several bacitracins
have been described in the literature, the most
thoroughly researched is bacitracin A (7), a cyclic
decapeptide with four of the aminoacids (glutamic,
ornithine, phenylalanine, and asparagine) in the
D-configuration. The molecule contains a thiazoline ring
structure and exhibits potent antibiotic activity against
Gram-positive bacteria (Pavli and Kmetec 2006).
Other decapeptides
Microorganisms isolated from marine habitats have
emerged as a promising source of new bioactive
metabolites with potential for development into drugs
for treating human diseases (Davidson 1995). Loloa-
tins A (8) to D (Fig. 2) is a family of cationic cyclic
decapeptide antibiotics isolated from a tropical marine
B. laterosporus collected in Papua New Guinea.
Loloatins exhibit in vitro antimicrobial activity against
methicillin-resistant S. aureus, vancomycin-resistant
enterococci, and drug-resistant Streptococcus pneu-
moniae (Gerard et al. 1999). In addition to being the
most potent of the four family members, loloatin C is
also the only one active against the Gram-negative
strain E. coli, making it an interesting lead compound
for further development towards broad spectrum
antibiotics (Tuin et al. 2009).
The soil bacterium Aneurinibacillus migulanus
(formerly known as B. brevis) secretes the antibiotic
tyrothricin, a mixture of linear pentadecapeptides
(gramicidins A, B, and C) and backbone-cyclized
cationic decapeptides [gramicidin S (GS) (9) and
tyrocidins] (Mogi and Kita 2009).
GS (9) is an extremely powerful antibiotic drug
against a broad spectrum of both Gram-negative and
Gram-positive bacteria (Kondejewski et al. 1996).
Regrettably, 9 is very hemolytic which presently
restricts its use to topical applications (Xu et al. 1995).
GS (9) is also effective against several pathogenic
fungi, and Otoguro et al. (1988) reported nematocidal
activities of GS (9) and polymyxins against the pine
wood nematode Bursaphelenchus lignicolus. The
gramicidin S (9) was also studied for its efficiency in
inhibiting insect larvae (Nickerson and Schnell 1983).
Gramicidin S (9) and tyrocidines produced by
different strains of B. brevis share two identical
sequences of five different amino acids. Studies in
various laboratories have led to suggestions of a
possible regulatory function of tyrocidines in the
induction of sporulation through a selective inhibition
of RNA synthesis during cell differentiation. Despite
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its structural similarity to tyrocidine, gramicidin S (9)
does not inhibit RNA synthesis at the transcription
level but does inhibit the uptake of RNA precursors
during germination and, as a consequence, it may
delay spore outgrowth (Danders et al. 1982).
Consecutive single amino acid substitutions of
tyrocidin result in the A (10), B and C analogues (King
and Craig 1955). Tyrocidin is active against Gram-
negative bacteria and is used in a wide variety of
pharmaceutical compositions such as dental care
products, mouth wash, cough medicines and eye-
drops.
Gramicidin S (9), tyrocidine A (10) and gratisin
(GR) [cyclo(-Val1-Orn2-Leu3-D-Phe4-Pro5-D-Tyr6-)2]
(Fig. 2) are potent cyclopeptide antibiotics with the
amphiphilic b-sheet conformation. In view of wide-
spread resistance to antibiotics that has become a
serious threat to public health, amphiphilic antibiotics
are attractive targets for drug discovery. It has been
proposed that the principal modes of antibiotic action
result from an interaction of these antibiotics with the
cell membrane of the target microorganisms. More-
over, so far no resistance to the antibiotics has been
detected because it requires significant alteration of
the lipid composition of the cell membrane. Grami-
cidin S (9) and tyrocidine A (10) have very high
hemolytic activity, preventing their direct use in
combating microbial resistance. However, gratisin
showed significantly reduced toxicity against human
blood cells and high antimicrobial activity thus
proving to be a good drug candidate (Tamaki et al.
2009).
Nonapeptides
Polypeptin-permetin family and related
compounds
The cyclic depsipeptide permetin A (11) is one
member of the polypeptin-permetin family of antibi-
otics produced by B. circulans. The members of this
family, polypeptin A, permetin A (11) and BMY-
28160 have closely related structure, they have the
same b-hydroxyl fatty acid constituent and differ from
one other only by one or two amino acids (Fig. 3)
(Murai et al. 1985). Permetin A (11) was isolated from
B. circulans AJ 3902 and showed activity in vitro
against Gram-negative, Gram-positive and some
anaerobic bacteria (Yoko et al. 1979).
In the course of screening for new antibiotics with
broad antibacterial spectrum, B. circulans strain
H913-B4 was found to produce a novel antibiotic
coded as BMY-28160. Antibiotic BMY-28160 is
active against Gram-positive and Gram-negative bac-
teria, anaerobes and fungi. BMY-28160 is closely
related to permetin A (11), the difference being the L-
valine content in place of L-isoleucine in permetin A
(11) (Sugawara et al. 1984).
Polypeptin, a basic peptide antibiotic isolated from
B. circulans, contained 2 components, polypeptin A
and polypeptin B, which have identical amino acid
components but varied in the structure of the hydroxy
acid constituent attached to the a-amino group of the
peptide chain. Polypeptin A contained 3-hydroxy-4-
methylhexanoic acid and polypeptin B contained
3-hydroxy-5-methylhexanoic acid (Sogn 1976).
Octapeptides
Lipooctapeptides: octapeptin and related
compounds
Octapeptins are antibiotics, all octapeptides acylated
with a fatty acid residue, which differ with respect to
the ratio and the chirality of the constituent amino
acids and also in the nature of the fatty acid
substituent. Most, if not all, are broad-spectrum
antibiotics exhibiting good activity against P. aeru-
ginosa (Meyers et al. 1976).
Octapeptins A and B, previously named EM49,
have two different peptides: one comprised of five
2,4-diaminobutyric acid (DAB), one Phe, and two Leu
residues and the other comprised of five DAB and
three Leu residues. Each of these variants is acylated
Fig. 3 Nona- and Octapeptides
Phytochem Rev (2013) 12:685–716 697
123
with a C-10 or a C-11 b-hydroxy fatty acid. Moreover,
the EM49 antibiotics have been reported to have
moderate activity against yeasts and filamentous fungi
(Parker and Rathnum 1975). The antibiotic octapeptin
C1 (12), previously named 333-25 (Shoji et al. 1976b),
is an acylpeptide produced by a strain of B. circulans
(Fig. 3). It is active against Gram-positive and Gram-
negative bacteria (Kato and Shoji 1976).
Octapeptin D is another member of the octapeptin
group of antibiotics, produced by Bacillus strain JP-
301 (Shoji 1978). Octapeptin D is assumed to be a
complex of components which differ at the fatty acyl
residue. It appears to be an octapeptide in which the
c-amino groups of the three DAB residues were
uncovered and the N-terminal amino groups were
masked. Furthermore, a ring structure with a branched
chain was also suggested in which one DAB residue
was present at the branching point (Kato and Shoji
1980).
Heptapeptides
Lipoheptapeptides: iturins and surfactins families
Iturin family
The iturin family is of great biotechnological and
pharmaceutical interest. These are polar cyclic hepta-
peptides extracted from various strains of Bacillus spp.
These compounds contain one b-amino fatty acid and
seven a-amino-acids with D-tyrosin as the second
amino acid and two additional D-amino acids at
positions 3 and 6 (Fig. 4) (Chen et al. 2009c).
Numerous pharmacological properties have been
reported for various iturins, including potent anti-
fungal, antibiotic and antitumor activities (Trischman
et al. 1994). They exhibit strong antifungal activities
against a wide variety of pathogenic yeasts and fungi
but their antibacterial activities are restricted to some
bacteria such as Micrococcus luteus (Maget-Dana and
Peypoux 1994). The iturin group contains iturins A, C,
D and E, bacillomycin D, F and L, bacillopeptin and
mycosubtilin (Moyne et al. 2004).
Iturin A (13) is a cyclic lipopeptide produced
nonribosomaly by several strains of Bacillus spp.
with an aliphatic chain of the b-amino acid with 14
or 15 carbon atoms (Fig. 4) (Peypoux et al. 1978a).
Compound 13 exhibits antibacterial activity on M.
luteus (Maget-Dana and Peypoux 1994) but is more
effective against fungi and yeasts, passing through
the cell wall and disrupting the plasma membrane
with the formation of small vesicles and aggregation
of intramembranous particles (Thimon et al. 1995).
The antibiotic strength of iturin A (13) is related to
change in the permeability of the membrane cells
which leads to a leakage of K? from the intracellular
medium (Harnois et al. 1989). It has recently been
reported that iturin A (13) is the principal inhibitor in
the biocontrol activity of B. amyloliquefaciens
PPCB004 against postharvest fungal pathogens (Ar-
rebola et al. 2010). In addition, the lipopeptide iturin
A (13) is able to cause dose-dependent hemolysis in
human erythrocytes (Aranda et al. 2005).
Iturin C, normally found together with iturin A (13),
differs from it by the presence of an L-aspartyl residue
linked to the carboxyl group of the b-aminoacid in
spite of the L-asparaginyl residue in iturin A (13). In
contrast to iturin A (13), iturin C exhibits no antibiotic
activity (Peypoux et al. 1978b). Two novel metabo-
lites with long chain b-amino acid moieties of
different length were isolated from a strain of Bacillus
sp. as inhibitors of oxidized low density lipoprotein
(oxidized LDL) binding. These metabolites were
shown to be related to the cyclic lipopeptide iturin C
(Park et al. 1995).
Iturin D and iturin E, isolated from a strain of B.
subtilis producing iturin A (13), differ from iturin A
(13) by the presence of a free carboxyl group in iturin
D and a carboxymethyl group in iturin E. Iturin D and
iturin E exhibited strong antifungal activity against
yeasts and fungi but failed to exhibit any antibacterial
activity (Besson and Michel 1987).
Bacillomycin D (14), previously reported by Rau-
bitschek and Dostrovsky (1950) as an antifungal crude
preparation isolated from a strain of B. subtilis, was
later classified in the iturin group (Besson et al. 1976).
Bacillomycin D (14) is a mixture of two homologous
lipopeptides: the lipid moiety consists of 3-amino-12-
methyltridecanoic or 3-amino-12-methyltetradeca-
noic acid; the peptide moiety contains one residue of
each of the following seven amino acids: D-asparagine,
L-aspartate, L-glutamate, L-proline, D-serine, L-threo-
nine and D-tyrosine (Peypoux et al. 1981). Bacillomy-
cin D (14) has also been isolated from an endophytic
B. vallismortis ZZ185 which exhibited strong inhibi-
tion of the growth of several phytopathogenic fungi,
including Fusarium graminearum, Alternaria alter-
nata, Phytophthora capsici and Rhizoctonia solani
(Zhenzhen et al. 2010).
Bacillomycin F is a cyclic peptidolipid isolated
from B. subtilis. Preliminary studies have shown that
bacillomycin F belongs to the iturin group
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Fig. 4 Heptapeptides
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(Mhammedi et al. 1982), containing a peptide moiety
with L and D a-amino acids and a lipid moiety
principally consisting of a mixture of C16 and C17
b-amino acids. This antibiotic is related to iturin A
(13) and possesses the same sequence except for the
presence of an L-threonine instead of an L-serine
residue which is linked to the b-amino acid (Peypoux
et al. 1985).
Bacillomycin L is an antifungal agent isolated from a
strain of B. subtilis. The peptide moiety contains
D-aspartic acid, L-aspartic acid, L-glutamine, L-serine,
D-serine, L-threonine, and D-tyrosine. The lipid moiety is
a mixture of 3-amino-12-methyltridecanoic acid
(46 %), 3-amino-12-methyltetradecanoic acid (38 %),
3-amino-14-methylpentadecanoic acid (11 %) and 2
minor homologs (Besson et al. 1977). This antibiotic
lipopeptide belongs to the iturinic family of antifungal
agents and acts with a strict sterol-phospholipid depen-
dence on biomembranes (Volpon et al. 1999).
Bacillomycin Lc, a new antifungal antibiotic of the
iturin class, was isolated from a strain of B. subtilis as a
set of five congeners. The structure has been shown to
differ from that of bacillomycin L by sequence
changes from aspartate-1 to asparagine-1 and from
glutamine-5 to glutamate-5. The five congeners differ
from one other only in the structure of the aliphatic
side chain of the constituent b-amino acid (Eshita et al.
1995).
Bacillopeptins A (15), B (16), and C (17) (Fig. 4)
were identified as iturin-group antifungal antibiotics,
isolated from B. subtilis FR-2 (Kajimura et al. 1995).
Their structures were elucidated as cyclic lipopeptides
analogous to bacillomycin L, containing long-chain
b-amino acids and L-Asn and L-Glu instead of the
L-Asp and L-Gln residues found in bacillomycin L.
Bacillopeptin C (17) proved active against yeasts and
fungi, whereas bacillopeptins A (15) and B (16) did
not exhibit any activity at 100 lg/mL.
Mycosubtilin (18), isolated from B. subtilis, is a
cyclopeptide consisting of seven a-amino acids closed
by a b-amino acid linkage similar to that found in other
antibiotics of the iturin group (Peypoux et al. 1986).
This compound has a strong lytic action on erythro-
cytes (Besson et al. 1989). Mycosubtilins B and C
were isolated from B. subtilis and differ by the
presence of a carboxyl group and carboxymethyl
group respectively instead of a carboxamide group in
previously described mycosubtilin (18) (Besson and
Michel 1990).
Surfactin family
Surfactins, powerful amphiphilic membrane-active
biosurfactant lipoheptapeptides with a structure sim-
ilar to that of iturins, are not fungitoxic by themselves
but do have some synergistic effects on the antifungal
activity of iturin A (13) (Maget-Dana et al. 1992).
Surfactin (19), produced by Bacillus species like B.
subtilis (Rahman et al. 2006), B. amyloliquefaciens
(Sun et al. 2006), B. licheniformis (Tendulkar et al.
2007), and B. natto (Kameda et al. 1974), is a
heptapeptide with an LLDLLDL chiral sequence linked
by a b-hydroxy fatty acid consisting of 13–15 carbon
atoms to form a cyclic lactone structure (Fig. 4) (Chen
et al. 2009c).
The antagonistic lipopeptide surfactin (19),
secreted by B. licheniformis BC98, had significant
activity against different phytopathogenic fungi
including Magnoporthe grisea (Tendulkar et al. 2007).
Surfactin (19) possessed antimicrobial (Vater
1986), antiviral (Kracht et al. 1999; Vollenbroich
et al. 1997a), antitumor (Kameda et al. 1974),
hemolytic (Kikuchi and Hasumi 2002), blood antico-
agulant and fibrinolytic (Kim et al. 2006) activities. As
one of the strongest biosurfactants (Nicolas 2003),
surfactin (19) has numerous environmental and bio-
technological applications (Solaiman 2005) and has
proven to be particularly useful in oil recovery
(Youssef et al. 2007), remediation of soil contami-
nated by heavy metals (Mulligan 2005) and biocontrol
against phytopathogens (Bais et al. 2004) and insects
(Assie et al. 2002). Diverse new properties have been
identified including emulsification, foaming (Razafin-
dralambo et al. 1998) inhibition of star-fish oocyte
maturation (Toraya et al. 1995) and antimycoplasmic
activities (Vollenbroich et al. 1997b).
The biological role of surfactin (19) is believed to
support the colonization of surfaces and acquisition of
nutrients through their surface-wetting and detergent
properties. Surfactin (19) synthesized by B. amyloliq-
uefaciens FZB42 protects it against bacteria and
enables it to form biofilms thus equipping bacterium
with powerful antagonistic advantages during surface
colonization (Chen et al. 2009a).
The production of the lipopeptide biosurfactants
lichenysins by various strains of B. licheniformis has
been reported during the past few years (Jenny et al.
1993). Interest in such compounds has increased
because of their successful applications for in situ
microbial oil recovery and dispersion of oil spills
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(Clark et al. 1981). Elucidation of their structures has
shown that the basal structure is similar to that of
surfactin (19), the basic difference between surfactin
(19) and lichenysin turning out to be an amide residue
at position 1 (Gln) or 5 (Asn) in lichenysin instead of
an acidic one in the case of surfactin (Grangemard
et al. 1999).
Eight types of lichenysin commonly produced by B.
licheniformis are lichenysin A (20), lichenysin B,
lichenysin C, lichenysin D, lichenysin G, [Val7]
lichenysin G, [Ile4] lichenysin G and [Ile2,4] licheny-
sin G (Yakimov et al. 1995; Konz et al. 1999; Danders
et al. 1982). Differences in lichenysin types are due to
the kinds and sequences of amino acids in the lactone
ring (Li et al. 2008).
Lichenysin A (20) is a cyclic halotolerant lipohep-
tapeptide (Yakimov et al. 1997) produced by several
B. licheniformis strains (Yakimov et al. 1995; Gran-
gemard et al. 2001; Yakimov et al. 1999). The
antibiotic activity of lichenysins was shown to be
lower than that of surfactin (19) (Yakimov et al. 1995)
but they are more potent surfactants than surfactins,
thus emphasizing the predominant role of the carboxyl
group in the aggregation process (Grangemard et al.
1999). Lichenysins are also produced by other Bacil-
lus species such as a soil microorganism identified as
B. megaterium (Pueyo et al. 2009).
Halobacillin (21) is an acylpeptide similar to surf-
actin (19) and is produced by a Bacillus species; culture
CND-914, isolated from a deep-sea sediment core.
Halobacillin (21) exhibited moderate human cancer cell
cytotoxicity but, in contrast to the iturins, no antifungal
or antibiotic activity (Trischman et al. 1994).
A complex of metabolites consisting of two
isomeric cyclic acylpeptides identified as isomers of
halobacillin (21) was isolated from a culture of
Bacillus sp. A1238. The complex was designated
isohalobacillin. Each molecule of isohalobacillin
subcomponents contains either a 3-hydroxy-1-oxo-
13-methyltetradecyl or a 3-hydroxy-1-oxo-12-methyl-
tetradecyl moiety instead of the 3-hydroxy-1-oxopen-
tadecyl moiety found in the halobacillin (21). It
inhibited Acyl-CoA: cholesterol acyltransferase activ-
ity: cholesterol acyltransferase, a microsomal enzyme
that catalyzes the synthesis of cholesteryl esters from
acyl-CoA and cholesterol, plays key roles in both
intestinal absorption of cholesterol and cholesteryl
ester accumulation in macrophages (Hasumi et al.
1995).
Bamylocin A (22), a novel lipopeptide related to
surfactin (19) from B. amyloliquefaciens LP03 having
antagonistic and crude oil-emulsifying activity, was
isolated recently. As constituents of the peptide and
lipophilic part, seven amino acids and b-hydroxy-C13
fatty acid were determined (Lee et al. 2007).
Other cyclic lipopeptides related to surfactin (19)
are pumilacidins A (23), B, C, D, E, F and G, which
were isolated from the culture broth of a strain of B.
pumilus. They are cyclic acylheptapeptides composed
of a b-hydroxy fatty acid, two L-leucine, two
D-leucine, L-glutamic acid, L-aspartic acid and L-
isoleucine (or L-valine). Pumilacidins A (23), C and E
contain L-isoleucine at the C-terminal, while pumi-
lacidins B, D, F and G have L-valine at this position.
Pumilacidin screened as an antiviral antibiotic active
against herpes simplex virus was found to have
inhibitory activity against gastric H?, K?-ATPase
and to be protective against gastric ulcers in vivo
(Naruse et al. 1990). A strong inhibitory activity
against the fungi R. solani, Pythium aphanidermatum
and Sclerotium rolfsii was exhibited by pumilacidin
isolated from the cassava endophyte B. pumilus
MAIIIM4a in Brazil (Pereira de Melo et al. 2009).
The implication of pumilacidin was also reported in
food poisoning from a B. pumilus strain. The ability of
pumilacidin to inactivate oxidative phosphorylation in
mitochondria due to destruction of the cell membrane
was suggested to explain some of the symptoms (From
et al. 2007).
Three new lipopeptides (24–26), members of the
surfactins family, were recently isolated from B.
amyloliquefaciens BO7 (Fig. 4). These newly charac-
terized lipopeptides exhibited a strong inhibitory
activity against Fusarium oxysporum, an economi-
cally important fungal pathogen affecting a large
number of different crop plants, highlighting their
potential role in biocontrol activity of B. amylolique-
faciens (Romano et al. 2011).
Hexapeptides
Fusaricidins A (27), B, C and D, antifungal antibiotics
more potent than bacillopeptins, were found to be
produced by B. polymyxa KT-8 (Kajimura and Kaneda
1997). They are cyclic hexadepsipeptides all contain-
ing 15-guanidino-3-hydroxypentadecanoic acid as a
side chain (Fig. 5). Fusaricidins strongly inhibit the
growth of various kinds of fungi and show strong
inhibitory activity against Gram-positive bacteria
(Kaneda and Kajimura 2002).
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A group of antibiotics characterized by high sulfur
content were found to be produced by a variety of
Bacillus species. Thiocillins I (28) and II were isolated
from B. cereus G-15 and thiocillins II and III from B.
badius AR-91. Also, the former two were probably
produced by B. megatherium I-13. Thiocillins I (28), II
and III show antimicrobial activity against Gram-
positive bacteria in vitro but not against Gram-
negative bacteria (Shoji et al. 1976c). The differences
between these antibiotics were clarified in their
structural units (Shoji et al. 1981).
Linear peptides
Gramicidins A, B, and C are linear pentadecapeptides
isolated from the soil bacterium A. migulanus (for-
merly known as B. brevis) together with the backbone-
cyclized cationic decapeptides gramicidin S (9) and
tyrocidins (Mogi and Kita 2009).
In contrast to gramicidin S (9) (Fig. 2), the structure
of linear gramicidins like gramicidin A is an uncon-
ventional b-helix (6.3 amino acid residues per turn)
with the alternating L- and D-amino acid composition
except for position 2 (Gly) (Wallace 1986). All side
chains point outward and linear gramicidins form
N-to-N termini dimeric ion channels (Wallace 1998)
which selectively transport alkaline metal cations and
protons across the lipid bilayer (Kelkar and Chatto-
padhyay 2007).
Five analogues of gramicidin A are also available
from the bacterial extracts. Whereas gramicidin B
differs from gramicidin A by a single Trp11 ? Phe
substitution, gramicidin C exhibits a Trp11 ? Tyr
replacement. In addition, a Val1 ? Ile modification
exists for each of these analogues (Vogt et al. 2003).
Another analogue, gramicidin K, contains formyl and
ethanolamine blocking groups and can be resolved
into two components, one of which contains tyrosine.
In lipid bilayer membranes, both components form
channels of considerably longer lifetime and some-
what lower conductance than gramicidin A. Gramici-
din K appears to be a lipopeptide that consists of a fatty
acyl chain attached to the ethanolamine of gramicidin
A (Koeppe et al. 1985).
Four compounds belonging to the class of lower
mass lipopeptides were isolated from B. thuringiensis
kurstaki HD-1. The four kurstakins were found to have
the same amino acid sequence, Thr-Gly-Ala-Ser-His-
Gln-Gln, but different fatty acids. Each lipopeptide
has a lactone linkage between the carboxyl terminal
amino acid and the hydroxyl group in the side chain of
the serine residue. Their antifungal activity was
demonstrated against Stachybotrys charatum (Hathout
et al. 2000).
Fig. 5 Hexapeptides
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Cerexins is a family of antibiotic peptides
produced by B. cereus. Cerexins A (29) (Fig. 6)
and C have been reported to be single entities
whereas cerexins B and D are complexes of four
acylpeptides whose only difference is a fatty acyl
residue (Shoji et al. 1979).
The constituent fatty acid of cerexin A (29), an
antibiotic active against Gram-positive bacteria, was
elucidated to be b-hydroxy isoundecanoic acid. The
asparaginyl asparagine linkage in the amino acid
sequence of the antibiotic proved to be a normal
a-carboxyl peptide bond (Shoji et al. 1976d).
Cerexin B is another amphoteric antibiotic pro-
duced by B. cereus, closely related to cerexin A (29).
The essential difference between them was shown to
be the replacement of serine and one valine residue in
cerexin A (29) by glycine and phenylalanine in cerexin
B (Shoji and Hinoo 1975). The constituent fatty acids
for cerexin B were elucidated to be b-hydroxy
isodecanoic acid, b-hydroxy decanoic acid, b-hydroxy
isoundecanoic acid and b-hydroxy anteisoundecanoic
acid (Shoji and Kato 1976b).
Cerexins C and D are closely related to cerexins A
(29) and B in their physical–chemical and antimicro-
bial properties. While active against Gram-positive
bacteria, they are somewhat less active than cerexin A
(29). The fatty acid constituents of cerexins A (29) and
C and cerexins B and D are essentially the same. It was
concluded that cerexins C and D are the acylpeptides
analogous to cerexins A (29) and B, respectively, in
which the c-hydroxylysine residue is replaced by a
lysine residue (Shoji et al. 1976e).
The tridecaptin group of antibiotics produced by
strains of B. polymyxa contains tridecaptins A (30), B
and C differing from one other in their fatty acid
components and amino acid residues (Fig. 6) (Kato
et al. 1978). Tridecaptins are assumed to be linear acyl
tridecapeptides active against Gram-negative and
Gram-positive bacteria in vitro and in vivo (Kato
et al. 1979). Each one of the three tridecaptins has been
reported to be a complex (Shoji et al. 1979).
Edeines is a mixture of closely related basic peptide
antibiotics produced by the B. brevis Vm4 strain.
These compounds are linear pentapeptide amides with
Fig. 6 Linear peptides
isolated from Bacillus genus
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an unusual amino acid composition; in addition to
glycine, the molecule consists of isoserine, b-tyrosine,
a,b-diaminopropionic acid, and 2,6-diamino-7-hydro-
xyazaleic acid. The glycine residue in edeine A (31) is
attached to the basic constituent, spermidine. In the
case of edeine B, the base is guanylspermidine
(N-guanyl-N0-(3-aminopropyl)-1,4-diaminobutane).
The structure of edeine D is similar to edeine A (31)
with b-phenyl-b-alanine substituting for b-tyrosine.
Edeine F is composed of amino acids: (S)-b-phenyl-b-
alanine, (S)-isoserine, (S)-2,3-diaminopropionic acid,
(2R,6S)-diamino-(7R)-hydroxyazaleic acid, glycine
and a polyamine guanidylspermidine (Fig. 6) (Wo-
jciechowska et al. 1983). It was shown that the free
ionizable carboxy group in the (2R,6S,7R)-2,6-dia-
mino-7-hydroxyazaleic acid moiety is not essential for
biological activity in these compounds (Czajgucki
et al. 2006).
Edeines exhibit a broad spectrum of antimicrobial
activity including Gram-positive and Gram-negative
bacteria, yeasts, mould (Chmara and Borowski 1968),
and mycoplasmas (Borysiewicz 1966), but their high
animal toxicity does not permit their application in
chemotherapy as antimicrobial agents. These peptides
have the ability to eliminate plasmids determining
antibiotic resistance from bacterial cells (Borowski
et al. 1977a) and they demonstrate considerable
immunosuppressive effects in mice (Borowski et al.
1977b). Edeine antibiotics specifically and reversibly
inhibit the biosynthesis of DNA (Kuryło-Borowska
and Szer 1972) and have the ability to differentiate
prokaryotic and eukaryotic microorganisms based on
differences in functioning and structure of the DNA
replicating systems (Woynarowska et al. 1979). Ede-
ines are also universal inhibitors of protein synthesis
(Obrig et al. 1971).
The strain B. licheniformis M-4 produces a hydro-
philic peptide with antifungal activity named fungicin
M4. It contains the amino acids Glu (8), Arg (5), Pro
(4), Tyr (8), Val (3), Met (2) and Orn (4). Its inhibitory
spectrum is limited to Microsporum canis CECT
2797, Mucor mucedo CECT 2653, Mucor plumbeus
CCM F 443, Sporothrix schenckii CECT 2799, B.
megaterium and Corynebacterium glutamicum CECT
78 (Lebbadi et al. 1994).
Bogorol cationic peptide antibiotics contain a
number of unusual structural features which include
the reduction of the C-terminal residue to valinol, an
N-terminal residue of 2-hydroxy-3-methylpentanoic
acid, the incorporation of four D-amino acids and the
presence of a dehydroamino acid. Bogorols show
selective and relatively potent activity against meth-
icillin-resistant S. aureus and vancomycin-resistant
Enterococcus spp., as well as moderate activity
against E. coli (Barsby et al. 2006). The most
representative compound of this family, bogorol A
(32), isolated from a strain of B. laterosporus obtained
from a marine habitat, was shown to have antimicro-
bial activity against several human pathogens includ-
ing S. aureus, E. coli, Enterococcus faecalis,
Stenotrophomonas maltophilia, Burkholderia cepacia
and C. albicans (Andersen et al. 2002; Barsby et al.
2001).
Esperin is an antibiotic isolated from a strain of B.
mesentericus (Ogawa and Ito 1951). Esperin contains
the sequence R-CH(OH)CH2CO-Glu-Leu-Leu-Val-
Asp-Leu-Leu(Val) where R is a mixture of C10H21,
C11H23, and C12H25, and the C-terminal residue
contains a 30 % replacement by valine, with a lactone
formed by the OH group of the fatty acid constituent
and the carboxylic acid function of the aspartic acid
residue (Thomas and Ito 1969).
Laterosporin A and laterosporin B are two very
similar antibiotics produced by B. laterosporus which
were active against Corynebacterium xerosis, S.
aureus and Mycobacterium phlei (Barnes 1949).
Di- and tripeptides
Two acyldipeptides, tupuseleiamides A (33) and B
(34) (Fig. 7), in which the amino acids both have the
nonprotein D configuration, are produced by a B.
laterosporus isolate obtained from a tropical marine
habitat. Studies on tupuseleiamide A (33) revealed the
presence of D-tyrosine and D-serine with a 7-methyl-
octanoyl fragment which accounted for the remaining
site of unsaturation. Analysis for tupuseleiamide B
(34) showed that it differed from tupuseleiamide A
(33) only in the methyloctanoyl fragment (Barsby
et al. 2002).
Bacilysin (35), also named tetaine (Kaminski and
Sokolowska 1973), is a dipeptide antibiotic containing
an epoxyaminoacid moiety, and L-alanine residue at
the N-terminus and a non-proteinogenic amino acid,
L-anticapsin, at the C-terminus (Rogers et al. 1965).
Bacilysin (35), produced by B. subtilis (Loeffler et al.
1986; Abraham 1965; Newton 1949), B. pumilus
(Chmara and Borowski, 1973; Steinborn et al. 2005)
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and B. amyloliquefaciens (Chen et al. 2009b), is active
against a wide range of bacteria like S. aureus,
Corynebacterium xerose and E. coli and against yeast
C. albicans due to the anticapsin moiety which is
released after uptake into susceptible cells (Chmara
et al. 1980).
Bacilipins A and B, unsaturated aliphatic N-con-
taining acids related to bacilysin (35), produced by B.
subtilis A14, are active against M. phlei. The action of
these antibiotics was enhanced when used as mixture
(Newton 1949).
Chlorotetaine is a natural product isolated from the
B. subtilis strain BGSC1E2 (Rapp et al. 1988a) and B.
amyloliquefaciens (Argüelles-Arias et al. 2009). It is
related to the longer known dipeptide bacilysin (35)
containing the new amino acid (R)-30-chloro-40-oxo-
20-hexenylalanine (Fig. 7). Chlorotetaine inhibited
various fungi and, at higher concentrations, Gram-
positive and Gram-negative bacteria. It is the first Cl-
containing dipeptide identified as a metabolite of B.
subtilis (Rapp et al. 1988a).
Rhizocticins are phosphonate-containing oligopep-
tide antibiotics produced by the Gram-positive bacte-
rium B. subtilis ATCC6633 (Michener and Snell 1949;
Rapp et al. 1988b). They are di- and tripeptide
antibiotics consisting of a variable amino acid at the N
terminus followed by arginine and the nonproteinogenic
amino acid (Z)-L-2-amino-5-phosphono-3-pentenoic
acid (APPA) (Borisova et al. 2010). Rhizocticins consist
of four antifungal hydrophilic peptide antibiotics:
L-arginyl-L-2-amino-5-phosphono-3-cis-pentenoic acid
(rhizocticin A (36)), L-valyl-L-arginyl-L-2-amino-5-
phosphono-3-cis-pentenoic acid (rhizocticin B); and
rhizocticin C and D which are the same as rhizocticin but
contain L-Ile and L-Leu, respectively, in place of L-Val
(Fig. 7) (Kino et al. 2009). Filamentous fungi as well as
the cultivated nematode Caenorhabditis elegans were
found to be sensitive to rhizocticin A (36), while
bacteria and the protozoan Paramecium caudatum were
not (Kugler et al. 1990).
Siderophores
Many organisms produce highly specific chelators
called siderophores in response to iron limitation.
These siderophores chelate and transport iron via
specific transport systems to promote cell growth and
primarily utilize either hydroxamic acids or catechols
for the chelating ligands. Most of the hydroxamate-
containing siderophores, including ferrichrome,
aerobactin, and mycobactins, contain x-N-hydroxy
L-amino acids. However, others such as schizokinen
(37) (Fig. 8) and ferrioxamine B, utilize 1-amino-x-
(hydroxyamino) alkane residues to bind ferric ion (Lee
and Miller 1983).
A specific siderophore is often synthesized by more
than one species of microbes. B. subtilis utilized 3
types of hydroxamate siderophores, ferrichromes
(Takimura et al. 2004), ferrioxamines (Ollinger et al.
2006) and shizokinen (37), each of which is taken up
by different transport systems (Schneider and Hantke
1993).
Fig. 7 Di- and Tripeptides
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Bacillus megaterium ATCC 19213 produces the
dihydroxamate siderophore schizokinen (37). This
compound was originally isolated as a factor active in
the initiation of cell division (Lankford et al. 1966;
Byers et al. 1967) and later shown to be important in
iron uptake (Mullis et al. 1971). Schizokinen (37)
consists of two residues of L-amino-3-(N-acetylhydr-
oxyamino) propane linked to the two terminal car-
boxyl groups of a citric acid residue by amide bonds
(Fig. 8). The two hydroxamate groups and the
hydroxyl and carboxyl groups on the citrate backbone
form the six coordination sites for ferric iron (Plow-
man et al. 1984).
The monohydroxamate siderophore N-deoxyschiz-
okinen was isolated from B. megaterium ATCC 19213
and identified as 4-[(3-(acetylhydroxyamino) propyl)
amino]-2-[2-[(3-(acetylamino) propyl) amino]-2-oxo-
ethyl]-2-hydroxy-4-oxo-butanoic acid. It has the same
carbon skeleton as schizokinen (37) but the hydroxyl
group on one hydroxamate is replaced by hydrogen
(Hu and Boyer 1995).
In addition to their high affinity for ferric ions, these
siderophores, schizokinen (37) and N-deoxyschizoki-
nen, chelate aluminum. Aluminum was absorbed by B.
megaterium ATCC 19213 through the siderophore
transport receptor providing an extra pathway for
aluminum accumulation into iron-deficient aluminum
accumulation (Hu and Boyer 1996).
The classical catecholate siderophores contain 2,3-
dihydroxybenzoic acid (2,3-DHB) at the iron binding
center of the molecule and siderophores based on this
moiety have been found in many bacterial species.
These microorganisms use orthologs of a common
four-gene operon for synthesis of 2,3-DHB from the
bacterial aromatic biosynthetic pathway. Thus, the
siderophore of B. licheniformis K11 (siderophore
K11) was determined to be a catechol type siderophore
which is produced generally by Bacillus spp. (Woo
et al. 2007).
The first example of a bacterial catecholate sider-
ophore to be structurally characterized was itoic acid
(2,3-dihydroxybenzoylglycine) isolated from low iron
fermentation cultures of B. subtilis (Ito 1993).
Bacillibactin (38), a catecholic trilactone (2,3-
dihydroxybenzoate-glycinethreonine) (Fig. 8) (Mie-
thke et al. 2006), is a hexadentate siderophore
produced by B. subtilis (Raza et al. 2008), B.
anthracis, B. cereus, B. thuringiensis (Wilson et al.
2006), B. amyloliquefaciens (Chen et al. 2009b) and B.
licheniformis (Temirov et al. 2003). Bacillibactin (38)
and many of the siderophores are synthesized nonrib-
osomally by large, multidomain enzymes termed as
Fig. 8 Siderophores
isolated from Bacillus genus
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nonribosomal peptide synthetases (NRPS) that can
assemble peptides of wide structural diversity and
broad biological activity (Konz and Marahiel 1999).
Bacillibactin (38) binds iron through three 2,3-catech-
olamide moieties linked to a trithreonine scaffold via
glycine spacers (Abergel et al. 2009).
The majority of all catecholate siderophores which
have been structurally characterized are 2,3-dihydrox-
ybenzoate-containing species. In fact, only petrobac-
tin (39) and a related siderophore, petrobactin sulfate,
have been reported to contain the 3,4-dihydroxyl
substitution pattern (Garner et al. 2004).
The hexadentate 3,4-catecholate/citrate sidero-
phore petrobactin (39) is produced by the mammalian
pathogens B. anthracis (Koppisch et al. 2005) and B.
cereus (Wilson et al. 2006), apparently to evade the
immune protein siderocalin and mediate their iron
acquisition during infection; it is essential for the
pathogenicity of these organisms.
Bacillus anthracis, the causative agent of anthrax, is
a Gram-positive, spore-forming bacterium that readily
infects a variety of mammals. Targeted inhibition of
the biosynthesis of the essential siderophore petrobac-
tin (39), may hold promise as a potential therapeutic
treatment against anthrax. Several studies have
focused on characterizing the enzymes responsible
for petrobactin (39) biosynthesis and designing inhib-
itors for key biosynthetic steps (Pfleger et al. 2009).
Concluding remarks
Bacilli have been known for their biosynthetic
potential in the production of ribosomal and nonrib-
osomal bioactive natural products. In recent years,
great efforts have been made to elucidate the molec-
ular structures of an important number of bioactive
nonribosomal peptides isolated from Bacillus species
in order to discover the enzymatic mechanisms
involved in biosynthesis and to decipher the role
played by the genes involved and their regulation.
While knowledge is already available on the produc-
tion and characterization of a vast number of nonrib-
osomal peptides by bacilli, as indicated in this review
an important number of peptides structures remain
uncharacterized and a great deal of confusing data
about peptides abound in the literature.
Genomics has transformed the way in which we
think about these microorganisms and has greatly
influenced the manner in which we probe their
chemistry and biology. A large number of complete
and draft genome sequences are now available and
Bacillus is probably one of the best characterised
chemically and one of the most frequently represented
genera in the genomic databases bearing witness to the
importance of this genus in environmental processes,
industrial applications and medicine.
Hopefully, this information will contribute to a
better understanding of the features that divide this
family into pathogens and environmental and indus-
trial isolates. Furthermore, the genomic data will
contribute to a deeper understanding of ecological
adaptations when correlating genes with pathogenic
potential and with the production of bioactive peptides
and metabolites in general, and will help to charac-
terize the vast number of bioactive nonribosomal
peptides whose structures remain unresolved.
Although a vast number of bioactive peptides from
Bacillus genus have been reported, we now know that,
in general, conventional natural product isolation
programs vastly underestimated their biosynthetic
ability, in many cases by upwards of 80–90 % (Nett
et al. 2009). As a consequence, orphan secondary
metabolic gene clusters deduced from genome
sequencing efforts represent an unexplored resource
of new chemical entities that promise to provide a
novel source of bioactive peptides. Hence, one of the
greatest future challenges in this field will be to
develop general methods to trigger these silent gene
clusters and characterize the chemical biology of their
pathway products (Williams et al. 2008).
Further investigation of new antibiotic peptides and
their complex regulation of biosynthesis genes will
continue to be a fruitful approach to developing a more
complete understanding of the biology and metabolite
production by these bacteria (Harwood and Cranen-
burgh 2008). Future sequencing efforts will stimulate
the broader scientific community to search for new
peptides and lead structures for industrial applications:
biosurfactancts (Raaijmakers et al. 2010), plant bio-
protectants (Romano et al. 2011), pharmaceutical and
agrochemical development (Seydlova and Svobodova
2008), etc., and to exploit commercial strains opti-
mized for the biocontrol of pathogens (in plants and
animals) (Harwood and Cranenburgh 2008; Jourdan
et al. 2009), in order to prevent the post-harvest loss of
fruits and vegetables, such as probiotics (Hong et al.
2005) and for the production of other molecules of
Phytochem Rev (2013) 12:685–716 707
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industrial interest such as enzymes (amylases or
proteases) or native and heterologous proteins (Onge-
na and Jacques 2008).
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